纳武单抗成功治疗肝移植后播散性肝细胞癌
Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.
作者信息
Amjad Waseem, Kotiah Sandy, Gupta Ankur, Morris Michael, Liu Li, Thuluvath Paul J
机构信息
Institute of Digestive Health & Liver Disease, Mercy, Medical Center, Baltimore MD 21202, USA.
Departments of Oncology, Mercy, Medical Center, Baltimore MD 21202, USA.
出版信息
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):185-187. doi: 10.1016/j.jceh.2019.11.009. Epub 2019 Dec 5.
Abstract
The use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte-associated protein-4 and programmed death 1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.
摘要
由于移植受者使用免疫疗法会导致移植物丢失的风险非常高，因此被视为禁忌。鉴于细胞毒性T淋巴细胞相关蛋白4和程序性死亡1通路与移植物耐受性有关，移植物丢失是可以预料的。在本病例报告中，我们描述了一名复发性、播散性肝细胞癌女性患者，她接受免疫检查点抑制剂纳武单抗治疗获得成功。
相似文献
1
Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.纳武单抗成功治疗肝移植后播散性肝细胞癌
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):185-187. doi: 10.1016/j.jceh.2019.11.009. Epub 2019 Dec 5.
2
Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.纳武单抗治疗后肝移植失败——一例报告及系统文献研究
Transplant Direct. 2018 Jul 20;4(8):e376. doi: 10.1097/TXD.0000000000000814. eCollection 2018 Aug.
3
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.免疫疗法在肝移植围手术期治疗肝细胞癌中的应用：移植肿瘤学视角
Cancers (Basel). 2022 Mar 30;14(7):1760. doi: 10.3390/cancers14071760.
4
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
5
Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases.肝移植后转移性肝细胞癌的抗程序性细胞死亡蛋白1（PD-1）免疫治疗：三例报告
Cureus. 2020 Oct 25;12(10):e11150. doi: 10.7759/cureus.11150.
6
Immune Checkpoint Inhibitors in Organ Transplant Patients.器官移植患者中的免疫检查点抑制剂
J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180.
7
Use of checkpoint inhibitors in liver transplant recipients.在肝移植受者中使用检查点抑制剂。
United European Gastroenterol J. 2018 Aug;6(7):970-973. doi: 10.1177/2050640618774631. Epub 2018 Apr 30.
8
Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.从移植肿瘤学角度探讨肝癌肝移植受者的免疫治疗：综述
Ther Adv Med Oncol. 2019 Apr 26;11:1758835919843463. doi: 10.1177/1758835919843463. eCollection 2019.
9
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.肝细胞癌中的程序性细胞死亡蛋白 1（PD-1）/程序性死亡配体 1（PD-L1）轴：预后和治疗展望。
Clin Transl Oncol. 2019 Jun;21(6):702-712. doi: 10.1007/s12094-018-1975-4. Epub 2018 Nov 1.
10
Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.程序性死亡蛋白1、程序性死亡配体-1及细胞毒性T淋巴细胞相关分子4在肝细胞癌中的表达及预后意义
APMIS. 2017 Aug;125(8):690-698. doi: 10.1111/apm.12703. Epub 2017 May 11.
引用本文的文献
1
Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.关于肝癌患者肝移植后免疫治疗反应的当前知识。
J Liver Transpl. 2025 Aug;19. doi: 10.1016/j.liver.2025.100285. Epub 2025 Jun 6.
2
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.肝细胞癌辅助免疫治疗的进展：综述
Immunotargets Ther. 2025 Jun 25;14:631-654. doi: 10.2147/ITT.S528709. eCollection 2025.
3
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.展望未来：肝细胞癌的新兴疗法
Gastroenterol Hepatol (N Y). 2025 May;21(5):286-297.
4
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南
Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.
5
Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.免疫检查点抑制剂时代肝细胞癌的肝移植
Cancers (Basel). 2024 Jun 28;16(13):2374. doi: 10.3390/cancers16132374.
6
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.免疫疗法与肝移植：基础与临床数据的叙述性综述
Cancers (Basel). 2023 Sep 15;15(18):4574. doi: 10.3390/cancers15184574.
7
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology.辅助治疗中实体瘤的免疫检查点抑制剂：当前进展、未来方向及在移植肿瘤学中的作用
Cancers (Basel). 2023 Feb 23;15(5):1433. doi: 10.3390/cancers15051433.
8
Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?免疫疗法治疗肝移植后肝细胞癌复发，我们能否利用免疫检查点抑制剂的力量？
Front Immunol. 2023 Feb 16;14:1092401. doi: 10.3389/fimmu.2023.1092401. eCollection 2023.
9
Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review.肝移植背景下肝细胞癌的免疫治疗：综述。
Int J Mol Sci. 2023 Jan 25;24(3):2358. doi: 10.3390/ijms24032358.
10
Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review.低剂量程序性死亡受体1抑制剂联合乐伐替尼用于肝细胞癌肝移植术后复发的预防性治疗：病例报告及文献综述
Front Oncol. 2022 Sep 2;12:951303. doi: 10.3389/fonc.2022.951303. eCollection 2022.
本文引用的文献
1
Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.从移植肿瘤学角度探讨肝癌肝移植受者的免疫治疗：综述
Ther Adv Med Oncol. 2019 Apr 26;11:1758835919843463. doi: 10.1177/1758835919843463. eCollection 2019.
2
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.实体器官移植受者中癌症的检查点抑制剂治疗：机构经验和文献系统评价。
J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1.
3
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?免疫检查点阻断在晚期癌症器官移植患者中的应用：我们能走多远？
Curr Opin Oncol. 2019 Mar;31(2):54-64. doi: 10.1097/CCO.0000000000000505.
4
Use of checkpoint inhibitors in liver transplant recipients.在肝移植受者中使用检查点抑制剂。
United European Gastroenterol J. 2018 Aug;6(7):970-973. doi: 10.1177/2050640618774631. Epub 2018 Apr 30.
5
Immune Checkpoint Inhibitors in Organ Transplant Patients.器官移植患者中的免疫检查点抑制剂
J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180.
Zotero 插件